Ocular Therapeutix, Inc. (OCUL)

NGM – Real Time Price. Currency in USD

9.16

-0.12 (-1.29%)

At close: May 12, 2026, 4:00 PM EDT

9.13

-0.03 (-0.33%)

Pre-market: May 13, 2026, 4:39 AM EDT

13.05.2026

Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

08.05.2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to twelve newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

05.05.2026

Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

05.05.2026

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.37 per share a year ago.

05.05.2026

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF SOL-1 Week 52 data presentations held at Macula Society and VBS meetings reinforce AXPAXLI's unmatched durability and sustained disease control data in wet AMD Commercial preparedness plans accelerated as Ocular intends to submit AXPAXLI NDA based on SOL-1 Week 52 data, subject to ongoing formal discussions with the U.S. FDA SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline readout in 1Q 2027 HELIOS-3 Phase 3 trial in diabetic retinopathy ongoing Ocular to host Investor Day on Wednesday, June 17, 2026, in New York City, including key program and regulatory updates Cash balance of $666.7 million as of March 31, 2026, with expected runway into 2028 BEDFORD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.

29.04.2026

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial Subjects who have completed the two-year follow-up in either SOL-1 or SOL-R have an opportunity to enroll in the SOL-X trial for an additional three years SOL-X is designed to build on AXPAXLI's successful SOL-1 Phase 3 trial by exploring the potential to improve long-term visual outcomes with a dramatically reduced treatment burden BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the first patient has been enrolled in the SOL-X long-term extension trial for AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).

28.04.2026

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026.

Videos

No Data

There is no data to display

Press releases

08.05.2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05.05.2026

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

29.04.2026

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

22.04.2026

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Ocular's Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026 Ocular's Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026

Ocular Therapeutix, Inc. (OCUL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Videos

No Data

Press releases

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Videos

No Data

Press releases

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Search stocks

Ocular Therapeutix, Inc. (OCUL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Videos

No Data

Press releases

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Videos

No Data

Press releases

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Host Investor Day on June 17, 2026